ESTRO 2024 - Abstract Book

S5709

RTT - Patient experience and quality of life

ESTRO 2024

A skin reaction was reported by 12%. Abdominal pain (11%) and urinary pain (11%) were primarily mild or moderate (Table 3).

Table 1. Patient characteristics in the SOFT trial (n=121)

No. (%)

Patients

121

Age, median (range)

69 (40 – 86)

Gender

male

83 (69%) 68 (56%) 44 (36%)

PS

0 1 2

9 (7%)

OMD state

Recurrence Progressive

71 (59%) 39 (32%)

Induced De novo Prostate

7 (6%) 4 (3%)

Primary cancer

22 (18%) 21 (17%) 20 (17%) 14 (12%) 13 (11%) 31 (26%) 44 (36%) 61 (50%) 16 (13%) 60 (41%) 51 (35%) 20 (14%)

Colorectal

Lung

Urothelial cancer

Kidney Other¤

Prior systemic therapy

none

1-2 lines ≥ 3 lines

Target location

Liver

Lymph node Adrenal glands

Other

16 (11%)

Targets per course

1 2 3

96 (76%) 22 (17%)

9 (7%)

SOFT prescription dose

45 Gy/3 fx 50 Gy/5 fx 60 Gy/8 fx 67.5 Gy/3 fx 75 Gy/5 fx

57 (39%) 67 (46%)

7 (5%) 6 (4%) 3 (2%)

Other 7 (5%) Abbreviations: OMD= Oligo-metastatic disease; PS=performance status; No.=number of patients. , ¤Other primary cancers included: gynaecological cancer (n = 5), sarcoma (n=1), melanoma (n= 2), breast (n= 5), testis (n=1), thyroid (n= 1), esophagus (n= 2), cardia (n=1), HCC (n=1), pancreas (n=6), Cholangio- carcinoma (n=6).